NasdaqGS:SRPTBiotechs
A Look At Sarepta Therapeutics (SRPT) Valuation After Roche’s New Global Elevidys Phase 3 Trial
Roche’s decision to launch a new global Phase 3 trial of Elevidys, aimed at supporting a fresh approval push in Europe, puts Sarepta Therapeutics (SRPT) back in focus for investors watching Duchenne gene therapy.
See our latest analysis for Sarepta Therapeutics.
The fresh Elevidys trial comes as Sarepta’s share price has shown a 25.6% 1 month gain to US$21.55, yet the 1 year total shareholder return of about 60% decline highlights that long term holders have faced significant volatility and...